A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome

Back to Search
Print
Bookmark Trial

NCT00220363

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Schwarz
Monheim, , , Germany
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Overactive Bladder Syndrome
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Overactive Bladder Syndrome

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- less than 8 micturitions in 24 hours

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Overactive Bladder SyndromeFesoterodine "add-on" Male Overactive Bladder Study
NCT00546637
  1. Birmingham, Alabama
  2. Gilbert, Arizona
  3. Gilbert, Arizona
  4. Litchfield Park, Arizona
  5. Mesa, Arizona
  6. Phoenix, Arizona
  7. Tucson, Arizona
  8. La Mesa, California
  9. Newport Beach, California
  10. San Bernardino, California
  11. San Diego, California
  12. San Diego, California
  13. Aurora, Colorado
  14. Denver, Colorado
  15. Jupiter, Florida
  16. Orange City, Florida
  17. West Palm Beach, Florida
  18. Dunwoody, Georgia
  19. Evansville, Indiana
  20. Jeffersonville, Indiana
  21. Newburgh, Indiana
  22. Des Moines, Iowa
  23. Iowa City, Iowa
  24. Baltimore, Maryland
  25. Owings Mills, Maryland
  26. Watertown, Massachusetts
  27. Flint, Michigan
  28. St. Clair Shores, Michigan
  29. Troy, Michigan
  30. Utica, Michigan
  31. West Bloomfield, Michigan
  32. West Bloomfield, Michigan
  33. Minneapolis, Minnesota
  34. Omaha, Nebraska
  35. Sewell, New Jersey
  36. Albany, New York
  37. Garden City, New York
  38. Kingston, New York
  39. New York, New York
  40. Poughkeepsie, New York
  41. Syracuse, New York
  42. Williamsville, New York
  43. Durham, North Carolina
  44. Greensboro, North Carolina
  45. Fargo, North Dakota
  46. Fargo, North Dakota
  47. Cincinnati, Ohio
  48. Columbus, Ohio
  49. Columbus, Ohio
  50. Bethany, Oklahoma
  51. Portland, Oregon
  52. Bala Cynwyd, Pennsylvania
  53. Camp Hill, Pennsylvania
  54. Pittsburgh, Pennsylvania
  55. Charleston, South Carolina
  56. Greer, South Carolina
  57. Austin, Texas
  58. Austin, Texas
  59. Houston, Texas
  60. Tacoma, Washington
  61. Madison, Wisconsin
  62. Milwaukee, Wisconsin
  63. Antwerpen,
  64. Edegem,
  65. Leuven,
  66. Salvador, BA
  67. Curitiba, PR
  68. Rio de Janeiro, RJ
  69. Porto Alegre, RS
  70. São Paulo, SP
  71. Campos do Jordão, São Paulo
  72. Victoria, British Columbia
  73. Winnipeg, Manitoba
  74. Barrie, Ontario
  75. North Bay, Ontario
  76. Toronto, Ontario
  77. Toronto, Ontario
  78. Chicoutimi, Quebec
  79. Pointe-Claire, Quebec
  80. Sherbrooke, Quebec
  81. Medellin, Antioquia
  82. Bogota, Cundinamarca
  83. Berlin,
  84. Frankfurt,
  85. Goettingen,
  86. Hagenow,
  87. Lauenburg,
  88. Leipzig,
  89. Oberursel,
  90. Wiesbaden,
  91. Ioannina, Ipiros
  92. Patras,
  93. Thessaloniki,
  94. Ludhiana, Punjab
  95. Lucknow, Uttar Pradesh
  96. Lucknow, Uttar Pradesh
  97. New Delhi,
  98. Bucheon-si, Gyunggi-do
  99. Pusan,
  100. Seoul,
  101. Seoul,
  102. Kuching, Sarawak
  103. Kuching, Sarawak
  104. Roermond,
  105. Tilburg,
  106. Zutphen,
  107. Bodø,
  108. Oslo,
  109. Cebu City, Cebu
  110. Bacolod City,
  111. Makati City,
  112. Manila,
  113. Manila,
  114. Quezon City,
  115. Bialystok,
  116. Gdansk,
  117. Gdansk,
  118. Lodz,
  119. Myslowice,
  120. Wroclaw,
  121. Singapore,
  122. Singapore,
  123. Banska Bystrica,
  124. Bratislava,
  125. Martin,
  126. Piestany,
  127. Skalica,
  128. Martorell, Barcelona
  129. Getafe, Madrid
  130. Manacor, Palma de Mallorca
  131. Boras,
  132. Jonkoping,
  133. Skovde,
  134. Stockholm,
  135. Stockholm,
  136. Ratchathewi, Bangkok
  137. Amphoe Mueang, Chiang Mai
Male
40 Years+
years
MULTIPLE SITES
Overactive Bladder SyndromeLong-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome
NCT00220402
  1. Monheim,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Overactive Bladder SyndromeA Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome
NCT00220363
  1. Monheim,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Overactive Bladder SyndromeLong-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome
NCT00220376
  1. RTP, North Carolina
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome
Official Title  ICMJE A Phase 3, Parallel Group, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled Multicenter Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome
Brief Summary

The trial consisted of a 2 week Run-In period, 12 week double-blind Treatment period and 2 week Safety Follow-Up period. Subjects were randomized to one of 4 treatment arms receiving either fesoterodine (SPM 907) 4mg, fesoterodine 8mg, active control (tolterodine SR 4mg) or placebo during the Double-Blind Treatment Period.

Two primary efficacy variables will be assessed for submission in the United States: change in the average number of micturitions (frequency) per 24 hours and the change in the average number of urge incontinence episodes per 24 hours. For the submissions in the European Union, the first primary variable will be the change in the average number of micturitions (frequency) per 24 hours and the co-primary variable is the treatment response, based on a treatment benefit scale. All continuous variables will be measured as changes from baseline to value after 12 weeks of treatment.

The most important safety variables included the assessment of adverse events, laboratory parameters, changes in ECG, physical exams and measurement of residual urine.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Condition  ICMJE Overactive Bladder Syndrome
Intervention  ICMJE Drug: SPM 907
Study Arms  ICMJE Not Provided
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE Not Provided
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE February 2005
Actual Primary Completion Date February 2005   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Overactive Bladder Syndrome

Exclusion Criteria:

  • less than 8 micturitions in 24 hours
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Not Provided
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Germany
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00220363
Other Study ID Numbers  ICMJE SP583
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Axel SteinertUCB Pharma
PRS Account Pfizer
Verification Date April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP